BioTrove, Inc. has announced an agreement with OncoMethylome Sciences for supply and use of BioTrove's OpenArray™ PCR screening technology in the development of DNA gene methylation cancer biomarkers.
"We look forward to enhancing our pharmacogenomic services with the BioTrove OpenArray system, which enables us to test our many proprietary methylation markers on clinical samples in a fast, high-throughput manner," said Wim Van Criekinge, Vice President, Biomarker and Pharmacogenomics Research, OncoMethylome.
Under the terms of the multi-year agreement, BioTrove will supply OncoMethylome with OpenArray nanoplates and instrumentation for use in research and development of DNA methylation-based biomarkers. Financial terms were not disclosed.
Gene methylation, a control mechanism that regulates gene expression in DNA, has become an important area of cancer diagnostics research. OncoMethylome products are designed to detect cancer cells and predict their response to cancer therapy by identifying specific methylation markers in patient DNA samples through PCR.
"Our supply agreement with OncoMethylome confirms the value of OpenArray technology in accelerating the development of diagnostic biomarkers - an important research area impacting patient health and treatment," said Al Luderer, Ph.D., president and CEO, BioTrove.
"Our company mission is to advance life science research through our technology, and we are especially pleased OncoMethylome has adopted our system for this purpose," Luderer added.